Creation of a long-acting nanoformulated dolutegravir

Brady Sillman, Aditya N. Bade, Prasanta K. Dash, Biju Bhargavan, Ted Kocher, Saumi Mathews, Hang Su, Georgette D Kanmogne, Larisa Y Poluektova, Santhi Gorantla, JoEllyn M McMillan, Nagsen Gautam, Yazen Alnouti, Benson J Edagwa, Howard Eliot Gendelman

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Potent antiretroviral activities and a barrier to viral resistance characterize the human immunodeficiency virus type one (HIV-1) integrase strand transfer inhibitor dolutegravir (DTG). Herein, a long-acting parenteral DTG was created through chemical modification to improve treatment outcomes. A hydrophobic and lipophilic modified DTG prodrug is encapsulated into poloxamer nanoformulations (NMDTG) and characterized by size, shape, polydispersity, and stability. Retained intracytoplasmic NMDTG particles release drug from macrophages and attenuate viral replication and spread of virus to CD4+ T cells. Pharmacokinetic tests in Balb/cJ mice show blood DTG levels at, or above, its inhibitory concentration of 64 ng/mL for 56 days, and tissue DTG levels for 28 days. NMDTG protects humanized mice from parenteral challenge of the HIV-1 strain for two weeks. These results are a first step towards producing a long-acting DTG for human use by affecting drug apparent half-life, cell and tissue drug penetration, and antiretroviral potency.

Original languageEnglish (US)
Article number443
JournalNature communications
Volume9
Issue number1
DOIs
StatePublished - Dec 1 2018

Fingerprint

human immunodeficiency virus
drugs
mice
macrophages
viruses
Viruses
half life
strands
inhibitors
blood
penetration
Pharmaceutical Preparations
Tissue
Poloxamer
Pharmacokinetics
T-cells
Macrophages
Chemical modification
Prodrugs
Polydispersity

ASJC Scopus subject areas

  • Chemistry(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Physics and Astronomy(all)

Cite this

Sillman, B., Bade, A. N., Dash, P. K., Bhargavan, B., Kocher, T., Mathews, S., ... Gendelman, H. E. (2018). Creation of a long-acting nanoformulated dolutegravir. Nature communications, 9(1), [443]. https://doi.org/10.1038/s41467-018-02885-x

Creation of a long-acting nanoformulated dolutegravir. / Sillman, Brady; Bade, Aditya N.; Dash, Prasanta K.; Bhargavan, Biju; Kocher, Ted; Mathews, Saumi; Su, Hang; Kanmogne, Georgette D; Poluektova, Larisa Y; Gorantla, Santhi; McMillan, JoEllyn M; Gautam, Nagsen; Alnouti, Yazen; Edagwa, Benson J; Gendelman, Howard Eliot.

In: Nature communications, Vol. 9, No. 1, 443, 01.12.2018.

Research output: Contribution to journalArticle

Sillman B, Bade AN, Dash PK, Bhargavan B, Kocher T, Mathews S et al. Creation of a long-acting nanoformulated dolutegravir. Nature communications. 2018 Dec 1;9(1). 443. https://doi.org/10.1038/s41467-018-02885-x
Sillman, Brady ; Bade, Aditya N. ; Dash, Prasanta K. ; Bhargavan, Biju ; Kocher, Ted ; Mathews, Saumi ; Su, Hang ; Kanmogne, Georgette D ; Poluektova, Larisa Y ; Gorantla, Santhi ; McMillan, JoEllyn M ; Gautam, Nagsen ; Alnouti, Yazen ; Edagwa, Benson J ; Gendelman, Howard Eliot. / Creation of a long-acting nanoformulated dolutegravir. In: Nature communications. 2018 ; Vol. 9, No. 1.
@article{8eae0681a4674b6c9aecb70da60d48f2,
title = "Creation of a long-acting nanoformulated dolutegravir",
abstract = "Potent antiretroviral activities and a barrier to viral resistance characterize the human immunodeficiency virus type one (HIV-1) integrase strand transfer inhibitor dolutegravir (DTG). Herein, a long-acting parenteral DTG was created through chemical modification to improve treatment outcomes. A hydrophobic and lipophilic modified DTG prodrug is encapsulated into poloxamer nanoformulations (NMDTG) and characterized by size, shape, polydispersity, and stability. Retained intracytoplasmic NMDTG particles release drug from macrophages and attenuate viral replication and spread of virus to CD4+ T cells. Pharmacokinetic tests in Balb/cJ mice show blood DTG levels at, or above, its inhibitory concentration of 64 ng/mL for 56 days, and tissue DTG levels for 28 days. NMDTG protects humanized mice from parenteral challenge of the HIV-1 strain for two weeks. These results are a first step towards producing a long-acting DTG for human use by affecting drug apparent half-life, cell and tissue drug penetration, and antiretroviral potency.",
author = "Brady Sillman and Bade, {Aditya N.} and Dash, {Prasanta K.} and Biju Bhargavan and Ted Kocher and Saumi Mathews and Hang Su and Kanmogne, {Georgette D} and Poluektova, {Larisa Y} and Santhi Gorantla and McMillan, {JoEllyn M} and Nagsen Gautam and Yazen Alnouti and Edagwa, {Benson J} and Gendelman, {Howard Eliot}",
year = "2018",
month = "12",
day = "1",
doi = "10.1038/s41467-018-02885-x",
language = "English (US)",
volume = "9",
journal = "Nature Communications",
issn = "2041-1723",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Creation of a long-acting nanoformulated dolutegravir

AU - Sillman, Brady

AU - Bade, Aditya N.

AU - Dash, Prasanta K.

AU - Bhargavan, Biju

AU - Kocher, Ted

AU - Mathews, Saumi

AU - Su, Hang

AU - Kanmogne, Georgette D

AU - Poluektova, Larisa Y

AU - Gorantla, Santhi

AU - McMillan, JoEllyn M

AU - Gautam, Nagsen

AU - Alnouti, Yazen

AU - Edagwa, Benson J

AU - Gendelman, Howard Eliot

PY - 2018/12/1

Y1 - 2018/12/1

N2 - Potent antiretroviral activities and a barrier to viral resistance characterize the human immunodeficiency virus type one (HIV-1) integrase strand transfer inhibitor dolutegravir (DTG). Herein, a long-acting parenteral DTG was created through chemical modification to improve treatment outcomes. A hydrophobic and lipophilic modified DTG prodrug is encapsulated into poloxamer nanoformulations (NMDTG) and characterized by size, shape, polydispersity, and stability. Retained intracytoplasmic NMDTG particles release drug from macrophages and attenuate viral replication and spread of virus to CD4+ T cells. Pharmacokinetic tests in Balb/cJ mice show blood DTG levels at, or above, its inhibitory concentration of 64 ng/mL for 56 days, and tissue DTG levels for 28 days. NMDTG protects humanized mice from parenteral challenge of the HIV-1 strain for two weeks. These results are a first step towards producing a long-acting DTG for human use by affecting drug apparent half-life, cell and tissue drug penetration, and antiretroviral potency.

AB - Potent antiretroviral activities and a barrier to viral resistance characterize the human immunodeficiency virus type one (HIV-1) integrase strand transfer inhibitor dolutegravir (DTG). Herein, a long-acting parenteral DTG was created through chemical modification to improve treatment outcomes. A hydrophobic and lipophilic modified DTG prodrug is encapsulated into poloxamer nanoformulations (NMDTG) and characterized by size, shape, polydispersity, and stability. Retained intracytoplasmic NMDTG particles release drug from macrophages and attenuate viral replication and spread of virus to CD4+ T cells. Pharmacokinetic tests in Balb/cJ mice show blood DTG levels at, or above, its inhibitory concentration of 64 ng/mL for 56 days, and tissue DTG levels for 28 days. NMDTG protects humanized mice from parenteral challenge of the HIV-1 strain for two weeks. These results are a first step towards producing a long-acting DTG for human use by affecting drug apparent half-life, cell and tissue drug penetration, and antiretroviral potency.

UR - http://www.scopus.com/inward/record.url?scp=85041667492&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85041667492&partnerID=8YFLogxK

U2 - 10.1038/s41467-018-02885-x

DO - 10.1038/s41467-018-02885-x

M3 - Article

C2 - 29402886

AN - SCOPUS:85041667492

VL - 9

JO - Nature Communications

JF - Nature Communications

SN - 2041-1723

IS - 1

M1 - 443

ER -